JP6347468B2 - 組換えフォンウィルブランド因子の投与による凝固疾患の治療 - Google Patents

組換えフォンウィルブランド因子の投与による凝固疾患の治療 Download PDF

Info

Publication number
JP6347468B2
JP6347468B2 JP2014514934A JP2014514934A JP6347468B2 JP 6347468 B2 JP6347468 B2 JP 6347468B2 JP 2014514934 A JP2014514934 A JP 2014514934A JP 2014514934 A JP2014514934 A JP 2014514934A JP 6347468 B2 JP6347468 B2 JP 6347468B2
Authority
JP
Japan
Prior art keywords
rvwf
fviii
composition
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014514934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516088A5 (enExample
JP2014516088A (ja
Inventor
フリードリッヒ シャイフリンガー
フリードリッヒ シャイフリンガー
ペーター タレセク
ペーター タレセク
ブルース イーウェンスタイン
ブルース イーウェンスタイン
ウィン イェン ウォン
ウィン イェン ウォン
トビアス エム． スーター
トビアス エム． スーター
Original Assignee
バクスアルタ ゲーエムベーハー
バクスアルタ ゲーエムベーハー
バクスアルタ インコーポレイテッド
バクスアルタ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスアルタ ゲーエムベーハー, バクスアルタ ゲーエムベーハー, バクスアルタ インコーポレイテッド, バクスアルタ インコーポレイテッド filed Critical バクスアルタ ゲーエムベーハー
Publication of JP2014516088A publication Critical patent/JP2014516088A/ja
Publication of JP2014516088A5 publication Critical patent/JP2014516088A5/ja
Application granted granted Critical
Publication of JP6347468B2 publication Critical patent/JP6347468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2014514934A 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療 Active JP6347468B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016137381A Division JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Publications (3)

Publication Number Publication Date
JP2014516088A JP2014516088A (ja) 2014-07-07
JP2014516088A5 JP2014516088A5 (enExample) 2015-07-30
JP6347468B2 true JP6347468B2 (ja) 2018-06-27

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014514934A Active JP6347468B2 (ja) 2011-06-10 2012-06-11 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016137381A Active JP6527114B2 (ja) 2011-06-10 2016-07-12 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP2018246475A Pending JP2019048892A (ja) 2011-06-10 2018-12-28 組換えフォンウィルブランド因子の投与による凝固疾患の治療

Country Status (24)

Country Link
US (2) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2680402C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2020009788A (es) * 2018-03-21 2020-12-09 Takeda Pharmaceuticals Co Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.
KR20210134642A (ko) * 2019-02-01 2021-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf (rvwf)를 이용한 예방 치료 방법
US20220401524A1 (en) * 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
IL303089A (en) * 2020-11-24 2023-07-01 Band Therapeutics Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
BRPI0820271A2 (pt) 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
TWI670072B (zh) * 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
JP2013500743A (ja) * 2009-08-04 2013-01-10 バクスター・インターナショナル・インコーポレイテッド Ｆｖｉｉｉおよびｖｗｆがノックアウトされた遺伝子導入マウス−血友病ａモデル
ES3037386T3 (en) 2010-07-08 2025-10-01 Takeda Pharmaceuticals Co Method of producing recombinant high molecular weight vwf in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病

Also Published As

Publication number Publication date
EP3858375A1 (en) 2021-08-04
HRP20180962T1 (hr) 2018-10-19
RU2014100107A (ru) 2015-07-20
DK3858375T3 (da) 2024-04-15
JP2017019788A (ja) 2017-01-26
KR20200091476A (ko) 2020-07-30
ES2976169T3 (es) 2024-07-24
EP3858375B1 (en) 2024-03-20
PL3412305T3 (pl) 2021-05-31
LT2717905T (lt) 2018-10-10
CA2838845C (en) 2019-08-06
PT3412305T (pt) 2021-01-29
RU2017102679A3 (enExample) 2018-12-19
RU2017102679A (ru) 2018-12-19
FI3858375T3 (fi) 2024-04-17
TR201808823T4 (tr) 2018-07-23
SI2717905T1 (sl) 2018-09-28
EP3412305A1 (en) 2018-12-12
HK1257436A1 (zh) 2019-10-18
NZ618790A (en) 2015-07-31
RU2019103386A (ru) 2020-08-07
KR20140039285A (ko) 2014-04-01
HUE039317T2 (hu) 2018-12-28
ES2682249T3 (es) 2018-09-19
AU2012267458A1 (en) 2014-01-09
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
MX2013014543A (es) 2014-06-11
KR20190041032A (ko) 2019-04-19
EP3412305B1 (en) 2021-01-06
AU2022201518B2 (en) 2025-07-03
AU2017206235B2 (en) 2019-10-17
AU2016202299B2 (en) 2017-07-20
SG10202002591QA (en) 2020-05-28
MX350582B (es) 2017-09-11
US20160184403A1 (en) 2016-06-30
US20120316116A1 (en) 2012-12-13
RU2680402C2 (ru) 2019-02-21
CN107412743B (zh) 2021-07-02
ES2860450T3 (es) 2021-10-05
CN108210889A (zh) 2018-06-29
KR102319868B1 (ko) 2021-11-01
MX2020000083A (es) 2020-08-06
PT3858375T (pt) 2024-04-18
JP2019048892A (ja) 2019-03-28
EP2717905A1 (en) 2014-04-16
CN107412743A (zh) 2017-12-01
JP6527114B2 (ja) 2019-06-05
AU2020200026A1 (en) 2020-01-30
PT2717905T (pt) 2018-07-02
JP2014516088A (ja) 2014-07-07
RU2628537C2 (ru) 2017-08-18
DK3412305T3 (da) 2021-03-01
US9272021B2 (en) 2016-03-01
AU2017206235A1 (en) 2017-08-03
RU2019103386A3 (enExample) 2022-01-24
CN103732244A (zh) 2014-04-16
AU2022201518A1 (en) 2022-03-24
BR112013031795A2 (pt) 2016-12-20
AU2016202299A1 (en) 2016-05-05
SG10201604684WA (en) 2016-07-28
AR086904A1 (es) 2014-01-29
WO2012171031A1 (en) 2012-12-13
PL2717905T3 (pl) 2018-10-31
CA2838845A1 (en) 2012-12-13
DK2717905T3 (en) 2018-07-02
EP2717905B1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
JP6347468B2 (ja) 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20110071012A (ko) 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
JP2025128168A (ja) 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
JP7326246B2 (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20250387455A1 (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
TW202400221A (zh) 凝血因子x活化劑及其用於治療出血性疾病的製劑
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160413

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160608

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180523

R150 Certificate of patent or registration of utility model

Ref document number: 6347468

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250